Procept BioRobotics Corp. (PRCT)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1588978 · fiscal year ends in Dec
Closing price $20.29 on 29 Oct 2026; 52-week range $16.69 to $36.10.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $337.3M
- Revenue growth
- 22.7%
- Net income, last twelve months
- -$109.8M
- Earnings per share
- -$1.94
- Gross margin
- 64.2%
- Operating margin
- -33.9%
- Net margin
- -32.5%
- Free cash flow
- -$84.9M
- Return on equity
- -32.3%
- Market value
- $1.2B
- Cash
- $227.9M
- Debt
- $51.7M
- Debt to equity
- 0.15
- Shares outstanding
- 57.2M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $308.1M | -$103.9M | -$95.6M | -$1.72 | -$58.3M | 10-K filed 26 Feb 2026 |
| FY2024 | 31 Dec 2024 | $224.5M | -$96.6M | -$91.4M | -$1.75 | -$103.6M | 10-K filed 27 Feb 2025 |
| FY2023 | 31 Dec 2023 | $136.2M | -$109.2M | -$105.9M | -$2.24 | -$133.2M | 10-K filed 28 Feb 2024 |
| FY2022 | 31 Dec 2022 | $75.0M | -$80.7M | -$87.2M | -$1.96 | -$83.0M | 10-K filed 28 Feb 2023 |
| FY2021 | 31 Dec 2021 | $34.5M | -$54.2M | -$59.9M | -$3.63 | -$57.9M | 10-K filed 22 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $94.5M | -$26.9M | -$0.47 |
| Q1 FY2026 | 31 Mar 2026 | $83.1M | -$31.6M | -$0.56 |
| Q4 FY2025 | 31 Dec 2025 | $76.4M | -$29.8M | -$0.53 |
| Q3 FY2025 | 30 Sep 2025 | $83.3M | -$21.4M | -$0.38 |
| Q2 FY2025 | 30 Jun 2025 | $79.2M | -$19.6M | -$0.35 |
| Q1 FY2025 | 31 Mar 2025 | $69.2M | -$24.7M | -$0.45 |
| Q4 FY2024 | 31 Dec 2024 | $68.2M | -$18.9M | -$0.35 |
| Q3 FY2024 | 30 Sep 2024 | $58.4M | -$21.0M | -$0.40 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $270.4M | 87.8% |
| Non-US | $37.7M | 12.2% |
Company events
The newest 8-K filings of 47 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 2 Oct 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 24 Sep 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 4 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 10 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 29 Apr 2026 | 8-K | Results | 2.02, 9.01 |
| 6 Mar 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 26 Feb 2026 | 8-K | Investor update | 7.01 |
| 25 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 18 Sep 2025 | 8-K | Leadership change | 5.02, 9.01 |
| 6 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 25 Jul 2025 | 8-K | Results, Leadership change, Investor update | 2.02, 5.02, 7.01, 9.01 |
Every filing
The newest filings with the SEC of 115 held.
| Filed | Form | Period |
|---|---|---|
| 2 Oct 2026 | 8-K | 2 Oct 2026 |
| 24 Sep 2026 | 8-K | 23 Sep 2026 |
| 5 Aug 2026 | 10-Q | 30 Jun 2026 |
| 4 Aug 2026 | 8-K | 4 Aug 2026 |
| 10 Jun 2026 | 8-K | 9 Jun 2026 |
| 1 Jun 2026 | SD | – |
| 30 Apr 2026 | 10-Q | 31 Mar 2026 |
| 29 Apr 2026 | 8-K | 29 Apr 2026 |
| 22 Apr 2026 | DEFA14A | – |
| 22 Apr 2026 | DEF 14A | 9 Jun 2026 |
| 6 Mar 2026 | 8-K | 5 Mar 2026 |
| 26 Feb 2026 | S-8 | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 9 Sep 2026 | Nouri Alaleh, EVP, CLO, CORP. SEC. | Sale outside a trading plan | 297 | $20.95 | $6.2K | 127,737 | 10 Sep 2026 |
| 9 Sep 2026 | Templin Barry L, EVP, Chief Technology Officer | Sale outside a trading plan | 373 | $20.95 | $7.8K | 94,826 | 10 Sep 2026 |
| 9 Sep 2026 | Waters Kevin, EVP, CFO | Sale outside a trading plan | 373 | $20.95 | $7.8K | 180,355 | 10 Sep 2026 |
| 7 Aug 2026 | Wood Larry L, President, CEO | Purchase | 23,900 | $20.85 | $498.3K | 23,900 | 10 Aug 2026 |
| 8 Jun 2026 | Nouri Alaleh, EVP, CLO, CORP. SEC. | Sale outside a trading plan | 285 | $28.48 | $8.1K | 105,069 | 10 Jun 2026 |
| 8 Jun 2026 | Waters Kevin, EVP, CFO | Sale outside a trading plan | 357 | $28.48 | $10.2K | 151,201 | 10 Jun 2026 |
| 8 Jun 2026 | Templin Barry L, EVP, Chief Technology Officer | Sale outside a trading plan | 358 | $28.48 | $10.2K | 68,953 | 10 Jun 2026 |
| 19 Mar 2026 | Nouri Alaleh, EVP, CLO, CORP. SEC. | Sale under a trading plan | 3,031 | $25.82 | $78.3K | 107,686 | 19 Mar 2026 |
| 19 Mar 2026 | Nouri Alaleh, EVP, CLO, CORP. SEC. | Sale under a trading plan | 2,332 | $26.15 | $61.0K | 105,354 | 19 Mar 2026 |
| 17 Mar 2026 | Nouri Alaleh, EVP, CLO, CORP. SEC. | Sale outside a trading plan | 304 | $28.15 | $8.6K | 110,717 | 19 Mar 2026 |
| 17 Mar 2026 | Waters Kevin, EVP, CFO | Sale outside a trading plan | 706 | $28.15 | $19.9K | 151,558 | 19 Mar 2026 |
| 10 Mar 2026 | Nouri Alaleh, EVP, CLO, CORP. SEC. | Sale outside a trading plan | 3,098 | $25.60 | $79.3K | 111,166 | 12 Mar 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 9 Sep 2026 | Nouri Alaleh, Officer | 297 | $6.2K | 9 Sep 2026 |
| 9 Sep 2026 | Templin Barry L, Officer | 373 | $7.8K | 9 Sep 2026 |
| 9 Sep 2026 | Waters Kevin, Officer | 373 | $7.8K | 9 Sep 2026 |
| 8 Jun 2026 | Nouri Alaleh, Officer | 285 | $8.1K | 8 Jun 2026 |
| 8 Jun 2026 | Waters Kevin, Officer | 357 | $10.2K | 8 Jun 2026 |
| 8 Jun 2026 | Templin Barry L, Officer | 358 | $10.2K | 8 Jun 2026 |
| 19 Mar 2026 | Alalah Nouri, Officer | 5,363 | $140.3K | 19 Mar 2026 |
| 17 Mar 2026 | Nouri Alaleh, Officer | 304 | $8.6K | 17 Mar 2026 |
| 17 Mar 2026 | Waters Kevin, Officer | 706 | $19.9K | 17 Mar 2026 |
| 10 Mar 2026 | Alalah Nouri, Officer | 3,243 | $81.9K | 10 Mar 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 29 Jul 2026 | BlackRock, Inc. | 13G amended | 8.2% | 4.6M |
| 18 May 2026 | AllianceBernstein L.P. | 13G amended | 0.3% | 147.3K |
| 30 Apr 2026 | Vanguard Capital Management | 13G | 5% | 2.8M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 6 Mar 2026 | FMR LLC | 13G amended | 2.9% | 1.6M |
| 17 Feb 2026 | T. Rowe Price Investment Management, Inc. | 13G | 5.9% | 3.3M |
| 11 Feb 2026 | BNP Paribas Asset Management Holding S.A. | 13G | 5.5% | 3.1M |
| 8 Jan 2026 | FMR LLC | 13G amended | 8.3% | 4.7M |
| 14 Nov 2025 | AllianceBernstein L.P. | 13G | 6.1% | 3.4M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 7.5M | +1% | 5.57 |
| 30 Sep 2026 | 7.4M | -0.17% | 5.32 |
| 15 Sep 2026 | 7.4M | +2.64% | 5.56 |
| 31 Aug 2026 | 7.2M | -5.92% | 8.56 |
| 14 Aug 2026 | 7.7M | +8.65% | 3.47 |
| 31 Jul 2026 | 7.1M | -8.54% | 5.12 |
| 15 Jul 2026 | 7.8M | +1.3% | 4.88 |
| 30 Jun 2026 | 7.7M | +0.57% | 3.89 |
Funds that hold it
From each fund's latest Form 13F.
291 funds held it at 30 Jun 2026: 136 added and 65 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 4,869,828 | $110.0M | +507,826 |
| T. Rowe Price Investment Management, Inc. | 3,265,704 | $73.7M | -8,090 |
| BNP Paribas Asset Management Holding S.A. | 2,823,849 | $63.8M | -265,529 |
| Vanguard Portfolio Management LLC | 2,526,802 | $57.1M | +105,440 |
| Vanguard Capital Management LLC | 2,460,802 | $55.6M | +61,735 |
| Chicago Capital, LLC | 2,073,237 | $46.8M | -87,350 |
| State Street Corp. | 1,617,475 | $36.5M | +87,844 |
| Geode Capital Management, LLC | 1,484,163 | $33.5M | +120,663 |
| FMR LLC | 1,444,878 | $32.6M | -17,026 |
| Price T Rowe Associates Inc. | 1,332,452 | $30.1M | +726,494 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $25.8B, market value $119.5B
- 3M Co. (MMM): revenue $25.2B, market value $91.6B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.9B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $54.0B
- Resmed Inc. (RMD): revenue $5.7B, market value $35.5B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $29.8B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $29.1B
- Medline Inc. (MDLN): revenue –, market value $27.5B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.3B
- Solventum Corp. (SOLV): revenue $8.3B, market value $14.2B